Country selection
To offer the best possible experience tailored to your national regulatory requirements and the available product portfolio, please choose your country from the following list. This option will be saved throughout the browser session. Thank you!
User experience & privacy
We use cookies to offer you an optimal website experience. This includes cookies necessary for the operation of the website and for the control of our commercial corporate goals, as well as those only used for anonymous statistical purposes, comfort settings or to display personalized content. Please note that based on your settings, not all functions of the website may be available. To find out more, please refer to our Data Privacy Statement.

Eckert & Ziegler Takes Measures to Significantly Increase U.S. Availability of GalliaPharm® Pharmaceutical Grade Germanium-68/Gallium-68 Generators

Berlin, Germany

Eckert & Ziegler Strahlen-und-Medizintechnik AG (EZAG), through its wholly owned subsidiary Eckert & Ziegler Radiopharma GmbH (EZR), recently submitted to the U.S. Food and Drug Administration (U.S. FDA) an amendment of its Drug Master File (DMF) for its pharmaceutical grade Germanium-68/Gallium-68 generator, GalliaPharm®. If found acceptable, the amendment will allow nuclear pharmacists to achieve a significantly higher number of elutions per generator and thereby increase the average availability of Gallium-68 in U.S. hospitals by about 40%.

EZAG is a world market leader for pharmaceutical grade Germanium-68/Gallium-68 generators and has recently seen a significant increase in the United States of the use of Gallium-68 labeled diagnostics for the detection of neuroendocrine tumors.

This increase in demand led to longer GalliaPharm® delivery times to radiopharmacies and raised concern among U.S. industry participants regarding the sufficient supply of these radioisotopes. EZAG has addressed these concerns by submitting extended stability data to the U.S. FDA, which reveal continuing safe use of EZAG’s GalliaPharm® generator at even higher number of elutions. If approved, the increased number of elutions per generator would in turn allow radiopharmacies and hospitals, to benefit from increased Gallium-68 supply for radiopharmaceutical application.

In addition to the increase of permitted elutions per GalliaPharm® generator, EZAG will also increase its overall production of GalliaPharm® generators beginning January 2019.

About Eckert & Ziegler.
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with around 800 employees, is one of the world’s largest providers of isotope-related components for radiation therapy and nuclear medicine.
Contributing to saving lives.

Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138,,

Note: This press release has been copied from


Get in touch

Contact us regarding your questions and we will get back to you as soon as possible.
By clicking send, you give your consent for processing your personal data in accordance with our Data Privacy Statement.
Permission required
In order to submit your request it is required to load a 3rd-party service (Google Re-Captcha spam protection system). You current privacy settings prevent this from happening automatically. By clicking the button below you explicitly allow to temporarily (on this page) load 3rd party services.